Non-Small Cell Lung Cancer Excellence Forum

Non-Small Cell Lung Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Edgardo Santos, Luis Raez, Federico Albrecht, Mark Socinski, John Heymach

Debates and Roundtables

Expert Roundtable: Biologic Differences Among EGFR/ERBB1 Mutations in Patients With Lung Cancer

10/27/2021

In part two of this virtual roundtable discussion, Dr Edgardo Santos et al discuss the biologic differences of EGFR and ERBB1 mutations observed in patients with lung cancer.

In part two of this virtual...

10/27/2021

Oncology

Debates and Roundtables

Expert Roundtable: OS Rates Among Patients With EGFR Mutations in the TKI Era

10/27/2021

In part one of this virtual roundtable discussion, Edgardo Santos, MD; Luis Raez, MD; Federico Albrecht, MD; Mark Socinski, MD; and John Heymach, MD, PhD, discuss the rates of overall survival among patients with EGFR mutations in the TKI era.

In part one of this virtual...

10/27/2021

Oncology

Videos

Dr Itchins Discusses Intermin Results From the ALKternate Clinical Trial

10/19/2021

Malinda Itchins, FRACP, PhD, Royal North Shore Hospital, Sydney, Australia, sits down with Oncology Learning Network to discuss the preliminary analysis of the ALKternate clinical trial.

Malinda Itchins, FRACP, PhD,...

10/19/2021

Oncology

Videos

Dr Gadgeel Discusses Pembrolizumab, Platinum-Based Chemo in EGFR/ALK-Positive NSCLC

09/29/2021

Shirish Gadgeel, MD, Henry Ford Health System, Detriot, MI, shares insight on pembrolizumab in combination with platinum-based chemotherapy in recurrent EGFR/ALK-Positive non-small cell lung cancer.

Shirish Gadgeel, MD, Henry Ford...

09/29/2021

Oncology

Debates and Roundtables

Expert Roundtable: Overcoming Resistance in KRAS G12C-Mutated NSCLC

09/29/2021

In part two of this virtual roundtable discussion, experts sat down with Oncology Learning Network to discuss overcoming resistance to KRAS G12C sensitive mutations in patients with lung cancer.

In part two of this virtual...

09/29/2021

Oncology

Debates and Roundtables

Expert Roundtable: Exploring the Treatment Landscape of KRAS G12C-Mutated NSCLC

09/29/2021

In part one of this virtual roundtable discussion, experts sat down with Oncology Learning Network to discuss KRAS G12C sensitive mutations in patients with lung cancer.

In part one of this virtual...

09/29/2021

Oncology

Interview

Dr Kennedy Discusses IMI for Nonpalpable Tumors

09/07/2021

Gregory T. Kennedy, MD, discusses findings from an original investigation on targeted intraoperative molecular imaging for localizing nonpalpable tumors and quantifying resection margin distances.

Gregory T. Kennedy, MD,...

09/07/2021

Oncology

Videos

Dr Baik Discusses Patritumab Deruxtecan for EGFR+ NSCLC

06/16/2021

Christina Baik, MD, MPH, discusses the efficacy and safety of patritumab deruxtecan therapy for patients with EGFR inhibitor-resistant EGFR+ NSCLC.

Christina Baik, MD, MPH,...

06/16/2021

Oncology

Videos

Dr Spira Talks Amivantamab Plus Lazertinib for Osimertinib-Relapsed, EGFR+ NSCLC

06/09/2021

Alexander Spira, MD, PhD, FACP, discusses the use of amivantamab in combination with lazertinib for the treatment of chemo-naïve patients with osimertinib-relapsed, EGFR+ NSCLC.

Alexander Spira, MD, PhD, FACP,...

06/09/2021

Oncology

Videos

Dr Bruno Highlights Racial Disparities in Testing, Trial Enrollment in NSCLC

06/07/2021

Dr Bruno, MD, discusses the racial disparities in biomarker testing and clinical trial enrollment in patients with NSCLC.

Dr Bruno, MD, discusses the...

06/07/2021

Oncology

Recent News

FDA Approval

FDA Approves Neoadjuvant/Adjuvant Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer

10/03/2024

Stephanie Holland ;

Based on results from the CHECKMATE-77T trial, the FDA has approved nivolumab plus platinum-doublet chemotherapy followed by surgical resection and single-agent nivolumab for patients with non-small cell lung cancer with no known EGFR...

Based on results from the...

10/03/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology